Management of the behavioural manifestations of Hunter syndrome

British Journal of Nursing : BJN
Jane RobertsShauna Kearney

Abstract

This article reviews the behavioural manifestations of, and the strategies for managing, Hunter syndrome (mucopolysaccharidosis (MPS) type II), a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulphatase. Hunter syndrome is generally considered to have two manifestations: an attenuated form and a severe form; in the latter, the person has pronounced cognitive decline. Infants with either phenotype usually appear normal at birth, but may show some somatic signs. Children with the severe phenotype show developmental delay and changes in behaviour patterns at about 18 months to 4 years of age. To varying degrees, patients with the severe form manifest behavioural disorders such as hyperactivity, aggression, impulsivity, anxiety and sleep disturbances. Medications, such as antipsychotics, benzodiazepines and anticonvulsants, have been tried with varying degrees of success. Behavioural management strategies may be a worthwhile approach, although published data are lacking. For sleep disturbances, behavioural modification plus melatonin or benzodiazepine may be effective treatments.

References

Jul 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·G BachE F Neufeld
Aug 1, 1983·Developmental Medicine and Child Neurology·I D Young, P S Harper
Jul 1, 1981·Child: Care, Health and Development·I D Young, P S Harper
Jul 1, 1995·Archives of Disease in Childhood·M C Bax, G A Colville
Sep 1, 1993·Archives of Disease in Childhood·M A Cleary, J E Wraith
Mar 31, 2005·Journal of Autism and Developmental Disorders·Annelies de BildtRuud Minderaa
Nov 23, 2005·Archives of Disease in Childhood·J FraserM B Delatycki
Aug 17, 2006·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Joseph MuenzerAlan Kimura
Mar 30, 2007·Acta Paediatrica. Supplement·Ida V D SchwartzRoberto Giugliani
Feb 5, 2008·Pediatrics·Rick MartinJoseph Muenzer
Jun 27, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·J Edmond WraithUNKNOWN HOS Investigators
Nov 11, 2009·Pediatrics·Joseph MuenzerE Wraith
Jan 30, 2010·Seminars in Hematology·Vinod K Prasad, Joanne Kurtzberg
Apr 27, 2011·Pediatrics·Joshua B HoltMaria L Escolar
May 3, 2011·The Journal of Pediatrics·Joshua HoltMaria L Escolar
Nov 9, 2011·Orphanet Journal of Rare Diseases·Maurizio ScarpaUNKNOWN Hunter Syndrome Europena Expert Council
Jan 11, 2012·Rheumatology·Joseph Muenzer
Mar 3, 2012·European Journal of Pediatrics·Barbara K Burton, Roberto Giugliani
Mar 8, 2013·European Journal of Pediatrics·Gabriel M CohnUNKNOWN Hunter Outcome Survey Investigators
Nov 6, 2013·Journal of Genetic Counseling·Mary NeedhamSeymour Packman

❮ Previous
Next ❯

Citations

May 18, 2017·International Journal of Molecular Sciences·Marika SalvalaioRosella Tomanin
Apr 8, 2020·Frontiers in Genetics·Caio Perez GomesJoão Bosco Pesquero
Apr 10, 2021·Orphanet Journal of Rare Diseases·Nathan Grant
May 1, 2021·Postgraduate Medical Journal·Lamiaa HamieMazen Kurban
Jul 13, 2021·Molecular Genetics and Metabolism·Julie B EisengartCara O'Neill
Aug 8, 2021·International Journal of Molecular Sciences·Christiane S HampeR Scott McIvor

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme replacement therapy

Software Mentioned

HUNTER

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.